ORGANON & CO (OGN) Stock Price, Quote, News and Overview
NYSE:OGN - New York Stock Exchange, Inc. - US68622V1061 - Common Stock - Currency: USD
OGN Quote, Performance and Key Statistics
15.49
-0.2 (-1.27%)
The current stock price of OGN is 15.49 USD. In the past month the price decreased by -5.61%. In the past year, price decreased by -16.27%.
OGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About OGN
Company Profile
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
Company Info
ORGANON & CO
30 Hudson Street, Fl 33
Jersey City NEW JERSEY US
CEO: Kevin Ali
Employees: 10000
Company Website: https://www.organon.com/
Investor Relations: https://www.organon.com/investor-relations/
Phone: 15514306000
ORGANON & CO / OGN FAQ
What is the stock price of ORGANON & CO today?
The current stock price of OGN is 15.49 USD. The price decreased by -1.27% in the last trading session.
What is the ticker symbol for ORGANON & CO stock?
The exchange symbol of ORGANON & CO is OGN and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is OGN stock listed?
OGN stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for ORGANON & CO stock?
14 analysts have analysed OGN and the average price target is 21.27 USD. This implies a price increase of 37.34% is expected in the next year compared to the current price of 15.49. Check the ORGANON & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORGANON & CO worth?
ORGANON & CO (OGN) has a market capitalization of 3.99B USD. This makes OGN a Mid Cap stock.
How many employees does ORGANON & CO have?
ORGANON & CO (OGN) currently has 10000 employees.
What are the support and resistance levels for ORGANON & CO (OGN) stock?
ORGANON & CO (OGN) has a support level at 15.43 and a resistance level at 15.98. Check the full technical report for a detailed analysis of OGN support and resistance levels.
Is ORGANON & CO (OGN) expected to grow?
The Revenue of ORGANON & CO (OGN) is expected to decline by -1.61% in the next year. Check the estimates tab for more information on the OGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ORGANON & CO (OGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OGN, evaluating the profitability, health, valuation and growth aspects
- ORGANON & CO (OGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORGANON & CO (OGN) Sales and EPS estimates to see what analysts future expectations are.
- ORGANON & CO (OGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORGANON & CO (OGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORGANON & CO (OGN) Stock Chart to make your own analysis
- ORGANON & CO (OGN) Latest news and press-releases to stay up to date.
Does ORGANON & CO (OGN) stock pay dividends?
ORGANON & CO (OGN) has a dividend yield of 7.14%. The yearly dividend amount is currently 1.15. Check the full fundamental report for a detailed analysis of OGN dividend history, reliability and sustainability.
When does ORGANON & CO (OGN) report earnings?
ORGANON & CO (OGN) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of ORGANON & CO (OGN)?
The PE ratio for ORGANON & CO (OGN) is 3.77. This is based on the reported non-GAAP earnings per share of 4.11 and the current share price of 15.49 USD. Check the full fundamental report for a full analysis of the valuation metrics for OGN.
What is the Short Interest ratio of ORGANON & CO (OGN) stock?
The outstanding short interest for ORGANON & CO (OGN) is 6.45% of its float. Check the ownership tab for more information on the OGN short interest.
OGN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OGN. When comparing the yearly performance of all stocks, OGN is a bad performer in the overall market: 74.4% of all stocks are doing better.
OGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to OGN. OGN has a medium profitability rating, but doesn't score so well on its financial health evaluation.
OGN Financial Highlights
Over the last trailing twelve months OGN reported a non-GAAP Earnings per Share(EPS) of 4.11. The EPS decreased by -0.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.3% | ||
| ROA | 10.2% | ||
| ROE | 263.89% | ||
| Debt/Equity | 17.73 |
OGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to OGN. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -4.34% and a revenue growth -1.61% for OGN